Abbott’s Next-Generation Spinal Cord Stimulator Gets FDA Nod
The newly approved Proclaim Plus system allows physicians to treat as many as six independent pain sites and choose the lowest-possible effective dose for each site.
You may also be interested in...
The US FDA approved Abbott's system that allows physicians to communicate with patients and remotely program their neuromodulation device.
Smith + Nephew is expanding its suite of simulation technologies to train surgeons on new techniques before they enter the operating room.
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.